Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

While these budgetary initiatives are welcome steps in the right direction, sustained policy efforts and global cooperation ...

A biosimilar medicine is a medicine that has a similar, but not identical, active ingredient to the reference (first) medicine. Because of this, a biosimilar should be thought of as being a medicine ...

Biosimilar Pipeline Analysis Market BURLINGAME, CA, UNITED STATES, February 6, 2025 /EINPresswire / -- The global Biosimilar Pip ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

To pave a pathway to producing a biosimilar version of atezolizumab, Mehmet Inan, PhD, director of the Izmir Biomedicine and Genome Center in Turkey, and his colleagues developed a bioprocess for ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Patent litigation reform could accelerate US biosimilar market entry, which lags behind the EU due to protracted legal processes. Biosimilar manufacturers face options like pre-clearance ...

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.